- Previous Close
34.46 - Open
34.38 - Bid 33.50 x --
- Ask 33.68 x --
- Day's Range
33.24 - 34.68 - 52 Week Range
29.32 - 72.30 - Volume
200,013 - Avg. Volume
203,540 - Market Cap (intraday)
2.314B - Beta (5Y Monthly) 2.38
- PE Ratio (TTM)
-- - EPS (TTM)
-24.14 - Earnings Date Feb 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
100.00
BICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing. The Biosciences segment provides instruments that enable the handling of cells and rare samples, and rapid transfer of liquids and reagents, as well as downstream analysis platforms. The Bioautomation segment offers end-to-end products and services in precision dispensing, advanced sample preparation, multiplex analysis and assay miniaturization, diagnostic and medical device manufacturing for life science and diagnostic industries. It primarily serves medical, pharmaceutical, and cosmetic industries. The company offers its products through sales organizations, as well as through an extensive distributor network. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was incorporated in 2016 and is headquartered in Gothenburg, Sweden.
www.bico.comRecent News: BICO.ST
View MorePerformance Overview: BICO.ST
Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BICO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BICO.ST
View MoreValuation Measures
Market Cap
2.43B
Enterprise Value
3.68B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.16
Price/Book (mrq)
0.88
Enterprise Value/Revenue
1.69
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-63.87%
Return on Assets (ttm)
-3.05%
Return on Equity (ttm)
-33.30%
Revenue (ttm)
2.42B
Net Income Avi to Common (ttm)
-1.5B
Diluted EPS (ttm)
-24.14
Balance Sheet and Cash Flow
Total Cash (mrq)
687.6M
Total Debt/Equity (mrq)
65.85%
Levered Free Cash Flow (ttm)
333.91M